cancer

Health By Elizabeth Cooney

Early trial shows promise aiming a modified cold-sore virus against brain tumors in children

Pharmalot By Ed Silverman

Clinical study reports hold more details about the side effects of cancer drugs

Politics By Lev Facher

Inside the White House’s push for a new, $6.5 billion agency aimed at curing cancer 

Biotech By Adam Feuerstein

Natural killer cells, primed with an antibody, induce remissions in patients with advanced blood cancer

Health By Eric Boodman

Virtual Event: What gene-targeted therapies mean for patients with cancer

Biotech By Adam Feuerstein

The biotech scorecard for the second quarter: 18 stock-moving events to watch

Pharmalot By Ed Silverman

FTC seeks to block Illumina from buying Grail, citing threats to competition

Biotech By Adam Feuerstein

The future of cancer immunotherapy: your questions, answered

Biotech By Adam Feuerstein

FDA approves first personalized cell therapy for patients with multiple myeloma

Biotech By Andy Rosen — Boston Globe

Broad Institute launches $300 million effort to harness AI to fight diseases

Biotech By Adam Feuerstein

STAT Webinar: Future directions for cancer immunotherapy

Pharma By Matthew Herper and Damian Garde

After leading a corporate turnaround, a swashbuckling CEO flies AstraZeneca into turbulence

Health By Meghana Keshavan

What ‘Beans’ taught her parents about pediatric cancer, the need for research, and patient advocacy

Biotech By Adam Feuerstein

A Rubius drug derived from red blood cells produces anti-tumor responses — and more questions

Pharmalot By Ed Silverman

Pharmalittle: U.S. sits on millions of AstraZeneca vaccine doses; WTO again fails to act on Covid-19 proposal

Health Tech By Casey Ross

4 lessons from IBM’s failure to transform medicine with Watson Health

Biotech By Adam Feuerstein

With data on a cancer drug derived from red blood cells looming, Rubius Therapeutics seeks to shed its bumbling image

A STAT Investigation By Casey Ross and Mario Aguilar

Inside the fall of Watson Health: How IBM’s audacious plan to ‘change the face of health care’ with AI fell apart

By Matthew Herper

Amgen spends $1.9 billion on Five Prime, eyeing an expansion in Asia

Health By Alissa Ambrose

Beauty at the micro-scale: MIT’s 2021 images award winners

Politics By Nicholas Florko

Janet Woodcock revolutionized the way the FDA reviews cancer drugs, inspiring her supporters and raising concerns for detractors

First Opinion By Hil Moss

What cancer survivorship can teach us about Covid-19

Biotech By Matthew Herper

Moncef Slaoui, departing Warp Speed, raises $250 million to test his R&D philosophy in a new company

First Opinion By David Carr and H. Gilbert Welch

Editor’s note: This opinion piece is now outdated

A STAT Investigation By Casey Ross

Could AI tools for breast cancer worsen disparities? Patchy public data in FDA filings fuel concern